var data={"title":"Levetiracetam: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Levetiracetam: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6447?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=levetiracetam-patient-drug-information\" class=\"drug drug_patient\">see &quot;Levetiracetam: Patient drug information&quot;</a> and <a href=\"topic.htm?path=levetiracetam-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Levetiracetam: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187641\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Keppra;</li>\n      <li>Keppra XR;</li>\n      <li>Roweepra;</li>\n      <li>Roweepra XR;</li>\n      <li>Spritam</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187642\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Abbott-Levetiracetam;</li>\n      <li>ACT Levetiracetam;</li>\n      <li>Apo-Levetiracetam;</li>\n      <li>Auro-Levetiracetam;</li>\n      <li>Dom-Levetiracetam;</li>\n      <li>JAMP-Levetiracetam;</li>\n      <li>Keppra;</li>\n      <li>PHL-Levetiracetam;</li>\n      <li>PMS-Levetiracetam;</li>\n      <li>PRO-Levetiracetam;</li>\n      <li>RAN-Levetiracetam</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187668\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Anticonvulsant, Miscellaneous</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187644\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> When switching from oral to IV formulations, the total daily dose should be the same.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Myoclonic seizures:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Immediate release (tablets, oral solution, tablets for oral suspension): Initial: 500 mg twice daily; increase every 2 weeks by 500 mg/dose to the recommended dose of 1,500 mg twice daily. Efficacy of doses other than 3,000 mg/day has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Initial: 500 mg twice daily; increase every 2 weeks by 500 mg/dose to the recommended dose of 1,500 mg twice daily. Efficacy of doses other than 3,000 mg/day has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Partial onset seizures:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate release (tablets, oral solution, tablets for oral suspension): Initial: 500 mg twice daily; increase every 2 weeks by 500 mg/dose to the maximum recommended dose of 1,500 mg twice daily. Efficacy of doses &gt;3,000 mg/day has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended release: Initial: 1,000 mg once daily; increase every 2 weeks by 1,000 mg/day to a maximum of 3,000 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Initial: 500 mg twice daily; increase every 2 weeks by 500 mg/dose to a maximum of 1,500 mg twice daily. Doses &gt;3,000 mg/day have been used in trials; however, there is no evidence of increased benefit.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Tonic-clonic seizures:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Immediate release (tablets, oral solution, tablets for oral suspension): Initial: 500 mg twice daily; increase every 2 weeks by 500 mg/dose to the recommended dose of 1,500 mg twice daily. Efficacy of doses lower than the recommended dose of 1,500 mg twice daily has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Initial: 500 mg twice daily; increase every 2 weeks by 500 mg/dose to the recommended dose of 1,500 mg twice daily. Efficacy of doses other than 3,000 mg/day has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Loading dose (off-label):</b> Oral: Immediate release: Initial doses of 1,500 to 2,000 mg have been well-tolerated (Betts 2000; Koubeissi 2008), although the necessity of a loading dose has not been established</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Status epilepticus (off-label use):</b> IV: 1,000 to 3,000 mg administered at a rate of 2 to 5 mg/kg/minute (NCS [Brophy 2012]) <b>or </b>60 mg/kg as a single dose (maximum dose: 4,500 mg) (AES [Glauser 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Subarachnoid hemorrhage (seizure prophylaxis) (off-label use</b>\n      <b>): </b>IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Loading dose: 20 mg/kg (rounded to the nearest 250 mg) over 60 minutes (Szaflarski 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maintenance dose: 1,000 mg over 15 minutes every 12 hours for 7 days; may be increased to a maximum dose of 1500 mg every 12 hours if necessary (Szaflarski 2010)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187656\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=levetiracetam-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Levetiracetam: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Use oral solution in children &le;20 kg; oral solution, immediate release tablets, and tablets for oral suspension may be used in children &gt;20 kg. When switching from oral to IV formulations, the total daily dose should be the same.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Myoclonic seizures:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Immediate release (tablets, oral solution, tablets for oral suspension): Children &ge;12 years and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Children &ge;12 years and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Partial onset seizures:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate release (tablets, oral solution):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants 1 month to &lt;6 months: Initial: 7 mg/kg/dose twice daily; increase every 2 weeks by 7 mg/kg/dose to a recommended dose of 21 mg/kg/dose twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children 6 months to &lt;4 years: Initial: 10 mg/kg/dose twice daily; increase every 2 weeks by 10 mg/kg/dose to a recommended dose of 25 mg/kg/dose twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children and Adolescents 4 to &lt;16 years:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Oral solution: Initial: 10 mg/kg/dose twice daily; increase every 2 weeks by 10 mg/kg/dose to a recommended dose of 30 mg/kg/dose twice daily (maximum daily dose: 3,000 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Tablets:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">20 to 40 kg: Initial: 250 mg twice daily, increase every 2 weeks by 250 mg twice daily to the maximum recommended dose of 750 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">&gt;40 kg: Initial: 500 mg twice daily, increase every 2 weeks by 500 mg twice daily to the maximum recommended dose of 1,500 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents &ge;16 years: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate release (tablets for oral suspension):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;4 years and weighing 20 kg to 40 kg: Initial: 250 mg twice daily; increase every 2 weeks by 250 mg/dose to the maximum recommended dose of 750 mg twice daily.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;4 years (weighing &gt;40 kg) and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended release: Children &ge;12 years and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants 1 month to &lt;6 months: Initial: 7 mg/kg twice daily; increase every 2 weeks by 7 mg/kg/dose to a recommended dose of 21 mg/kg twice daily. In clinical trials the average daily dose was 35 mg/kg/day. Efficacy of lower doses has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children 6 months to &lt;4 years: Initial: 10 mg/kg twice daily; increase every 2 weeks by 10 mg/kg/dose to a recommended dose of 25 mg/kg twice daily. If the patient cannot tolerate 50 mg/kg/day, reduce the daily dose. In clinical trials the average daily dose was 47 mg/kg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents 4 to &lt;16 years: Initial: 10 mg/kg twice daily; increase every 2 weeks by 10 mg/kg/dose to the recommended dose of 30 mg/kg twice daily. If the patient cannot tolerate 60 mg/kg/day, reduce the daily dose. In clinical trials the average daily dose was 44 mg/kg/day and the maximum daily dose was 3,000 mg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents &ge;16 years: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Tonic-clonic seizures:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate release (tablets, oral solution):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children and Adolescents 6 to &lt;16 years: Initial: 10 mg/kg/dose twice daily; increase every 2 weeks by 10 mg/kg/dose to the recommended dose of 30 mg/kg twice daily. Efficacy of doses other than 60 mg/kg/day has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents &ge;16 years: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate release (tablets for oral suspension):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;6 years and weighing 20 kg to 40 kg: Initial: 250 mg twice daily; increase every 2 weeks by 250 mg/dose to the maximum recommended dose of 750 mg twice daily.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;6 years (weighing &gt;40 kg) and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents 6 to &lt;16 years: Initial: 10 mg/kg twice daily; increase every 2 weeks by 10 mg/kg/dose to the recommended dose of 30 mg/kg twice daily. Efficacy of doses lower than 60 mg/kg/day has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents &ge;16 years: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Status epilepticus (off-label use):</b> Infants, Children, and Adolescents: IV: 20 to 60 mg/kg administered at a rate of 2 to 5 mg/kg/minute (NCS [Brophy 2012]) <b>or</b> 60 mg/kg as a single dose (maximum dose: 4,500 mg) (AES [Glauser 2016]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187645\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187646\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Immediate release and IV formulations: </i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &gt;80 mL/minute/1.73 m<sup>2</sup>: 500 to 1,500 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 50 to 80 mL/minute/1.73 m<sup>2</sup>: 500 to 1,000 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 30 to 50 mL/minute/1.73 m<sup>2</sup>: 250 to 750 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;30 mL/minute/1.73 m<sup>2</sup>: 250 to 500 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">End-stage renal disease (ESRD) requiring hemodialysis: Dialyzable (50%); 500 to 1,000 mg every 24 hours; supplemental dose of 250 to 500 mg is recommended posthemodialysis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peritoneal dialysis (PD): 500 to 1,000 mg every 24 hours (Aronoff 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous renal replacement therapy (CRRT): 250 to 750 mg every 12 hours (Aronoff 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Extended release tablets: </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &gt;80 mL/minute/1.73 m<sup>2</sup>: 1,000 to 3,000 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 50 to 80 mL/minute/1.73 m<sup>2</sup>: 1,000 to 2,000 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 30 to 50 mL/minute/1.73 m<sup>2</sup>: 500 to 1,500 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;30 mL/minute/1.73 m<sup>2</sup>: 500 to 1,000 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ESRD requiring hemodialysis: Use of immediate release formulation is recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187647\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;display:inline\">No dosage adjustment necessary</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187617\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Keppra: 500 mg/5 mL (5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg/100 mL (100 mL); 1000 mg/100 mL (100 mL); 1500 mg/100 mL (100 mL); 500 mg/5 mL (5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg/5 mL (5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Keppra: 100 mg/mL (473 mL) [gluten free, lactose free; contains acesulfame potassium, methylparaben, propylparaben; grape flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg/mL (5 mL, 473 mL, 500 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Keppra: 250 mg [scored; contains fd&amp;c blue #2 (indigotine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Keppra: 500 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Keppra: 750 mg [scored; contains fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Keppra: 1000 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Roweepra: 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Roweepra: 750 mg [contains corn starch, fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Roweepra: 1000 mg [contains corn starch]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg, 500 mg, 750 mg, 1000 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Disintegrating Soluble, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Spritam: 250 mg, 500 mg, 750 mg, 1000 mg [spearmint flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release 24 Hour, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Keppra XR: 500 mg, 750 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Roweepra XR: 500 mg, 750 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg, 750 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187603\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46216158\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b>  Tablets for oral suspension and soluble disintegrating tablet both refer to Spritam.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874650\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Keppra: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021035s099,021505s038lbl.pdf#page=28&amp;token=h/GoBDroawDA3c9N+L0xZ4M333INnOBqQPFPvpWT92YUXr9byQQKQ2wxdtVEzuqskdPFEOqioXWzjrxMLSchK8uQGr9VuUHPDGX2ah36J18t7GQ0nJyqx/pYnuYtStQV&amp;TOPIC_ID=12546\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021035s099,021505s038lbl.pdf#page=28</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Keppra XR: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022285s025lbl.pdf#page=21&amp;token=Vuxfsa80ZLCc35D6scNhif81X0+hPqgX4vdz4APcUBBpSqsTXcnaFhi76K0quh0T1nDpA0HFxeoN3n5lXETRhvKQTnI5/m+6P6WzKyndX66sEFEEO15SsecVwVsfUoSh&amp;TOPIC_ID=12546\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022285s025lbl.pdf#page=21</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Spritam: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM487803.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/8bxp4YrxUVJFUAWh6274giXO38s8SakPIVPdnI0lcPgw==&amp;TOPIC_ID=12546\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM487803.pdf</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187620\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: For IV use only; infuse over 15 minutes.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Administer without regard to meals.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral solution: Administer with a calibrated measuring device (not a household teaspoon or tablespoon).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablet (immediate release and extended release): Only administer as whole tablet; do not crush, break or chew.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablet for oral suspension: Remove from blister by peeling back the foil (do not push tablet through the foil). Place whole tablet on the tongue with dry hand, follow with a sip of liquid and swallow only after tablet disintegrates. Do not swallow tablets intact. Partial tablets should not be administered. Tablet disintegrates in a mean time of 11 seconds (ranging from 2 to 27 seconds) in the mouth when taken with a sip of liquid.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternatively, allow whole tablet to disperse in a small volume of liquid (one tablespoon or enough to cover the tablet) in a cup; consume entire contents immediately; resuspend any residue by adding an additional small volume of liquid and swallow the full amount.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187618\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Myoclonic seizures:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Immediate-release tablets/oral solution/tablets for oral suspension:</i> Adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents 12 years and older with juvenile myoclonic epilepsy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>IV: </i>Adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents 12 years and older with juvenile myoclonic epilepsy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Partial-onset seizures:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Immediate-release tablets/oral solution/tablets for oral suspension:</i> Adjunctive therapy in the treatment of partial-onset seizures in adults and children 1 month and older (Keppra) or 4 years and older and more than 20 kg (Spritam) with epilepsy. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Extended-release tablets:</i> Adjunctive therapy in the treatment of partial-onset seizures in adults and adolescents 12 years and older with epilepsy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>IV:</i> Adjunctive therapy in the treatment of partial-onset seizures in adults and children 1 month and older with epilepsy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Primary generalized tonic-clonic seizures:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Immediate-release tablets/oral solution/tablets for oral suspension:</i> Adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in adults and children 6 years and older with idiopathic generalized epilepsy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>IV:</i> Adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in adults and children 6 years and older with idiopathic generalized epilepsy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25873118\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Status epilepticus; Subarachnoid hemorrhage (seizure prophylaxis)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187675\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Keppra may be confused with Keflex, Keppra XR</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">LevETIRAcetam may be confused with lamoTRIgine, levOCARNitine, levoFLOXacin</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Potential for dispensing errors between Keppra and Kaletra (lopinavir/ritonavir)</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187610\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Incidences are for all indications and populations (adults and children) unless otherwise specified.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Increased blood pressure (diastolic; infants and children: 17%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Behavioral problems (includes aggression, agitation, anger, anxiety, apathy, depersonalization, emotional lability, irritability, neurosis; children and adolescents: 7% to 38%; adults: 7% to 13%), headache (14% to 19%), psychotic symptoms (infants and children: 17%; adults: 1%), drowsiness (8% to 15%; immediate release 4,000 mg/day, no titration: 45%; serious [patients hospitalized]: &lt;1%), irritability (infants, children, and adolescents: 6% to 12%), fatigue (10% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Vomiting (children and adolescents: 15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness (15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Nasopharyngitis (7% to 15%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Aggressive behavior (children and adolescents: 10%; adults: 1%), dizziness (5% to 9%), pain (7%), lethargy (children and adolescents: 6%), insomnia (children and adolescents: 5%), depression (3% to 5%), vertigo (3% to 5%), emotional lability (2% to 5%), agitation (children and adolescents: 4%), nervousness (4%), ataxia (partial-onset seizures: 3%; includes abnormal gait, incoordination), falling (children and adolescents: 3%), mood changes (children and adolescents: 3%), confusion (2% to 3%), amnesia (2%), anxiety (2%), hostility (2%), paranoia (children and adolescents: 2%), paresthesia (2%), sedation (children and adolescents: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Upper abdominal pain (children and adolescents: 9%), decreased appetite (children and adolescents: 8%), diarrhea (6% to 8%), nausea (5%), anorexia (3% to 4%), constipation (children and adolescents: 3%), gastroenteritis (children and adolescents: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Eosinophilia (children and adolescents: 9%), bruise (children and adolescents: 3%), decreased white blood cell count (3%), decreased neutrophils (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Influenza (3% to 8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Neck pain (2% to 8%), arthralgia (children and adolescents: 2%), joint sprain (children and adolescents: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Conjunctivitis (children and adolescents: 2%), diplopia (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Otalgia (children and adolescents: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Nasal congestion (children and adolescents: 9%), cough (2% to 9%), pharyngolaryngeal pain (children and adolescents: 7%), pharyngitis (6% to 7%), rhinitis (2% to 4%), sinusitis (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Head trauma (children and adolescents: 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing and/or case reports: Abnormal hepatic function tests, acute renal failure, agranulocytosis, alopecia, anaphylaxis, angioedema, blurred vision, choreoathetosis, decreased hematocrit, decreased hemoglobin, decreased red blood cells, disturbance in attention, DRESS syndrome, dyskinesia, eczema, equilibrium disturbance, erythema multiforme, granulomatous interstitial nephritis (Chau 2012), hepatic failure, hepatitis, hyperkinesia, hyponatremia, leukopenia, memory impairment, myalgia, myasthenia, neutropenia, pancreatitis, pancytopenia (with bone marrow suppression in some cases), panic attack, personality disorder, pruritus, psychosis, skin rash, Stevens-Johnson syndrome, suicidal ideation, suicidal tendencies, thrombocytopenia, toxic epidermal necrolysis, weight loss</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187623\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity (eg, anaphylaxis, angioedema) to levetiracetam or any component of the formulation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187607\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression (impaired coordination, ataxia, abnormal gait, weakness, fatigue, dizziness, and somnolence), which may impair physical or mental abilities. Symptoms occur most commonly during the first month of therapy. Patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatologic reactions: Severe reactions, including toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS), have been reported in adults and children. Onset is usually within ~2 weeks of treatment initiation, but may be delayed (&gt;4 months); recurrence following rechallenge has been reported. Levetiracetam should be discontinued if there are any signs of a hypersensitivity reaction or unspecified rash; if signs or symptoms suggest SJS or TEN, do not resume therapy and consider alternative treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic effects: Decreases in red blood cell counts, hemoglobin, hematocrit, white blood cell counts, and neutrophils and increases in eosinophils have been observed. Cases of, agranulocytosis, pancytopenia, and thrombocytopenia have also been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Potentially life-threatening hypersensitivity reactions, including anaphylaxis, angioedema, hypotension, hives, rash and respiratory distress may occur after the first dose or at any time during treatment. If signs or symptoms of anaphylaxis or angioedema occur, discontinue levetiracetam immediately. If a clear alternative etiology for the symptoms cannot be determined, discontinue permanently.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypertension: Isolated elevations in diastolic blood pressure measurements have been reported in children &lt;4 years; however, no observable differences were noted in mean diastolic measurements of children receiving levetiracetam vs placebo. Similar effects have not been observed in older children and adults.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychiatric symptoms: Psychosis, paranoia, hallucinations and behavioral symptoms (including aggression, agitation, anger, anxiety, apathy, confusion, depersonalization, depression, emotional lability, hostility, hyperkinesias, irritability, nervousness, neurosis, and personality disorder) may occur; dose reduction or discontinuation may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Suicidal ideation: Pooled analysis of trials involving various antiepileptics (regardless of indication) showed an increased risk of suicidal thoughts/behavior (incidence rate: 0.43% treated patients compared to 0.24% of patients receiving placebo); risk observed as early as 1 week after initiation and continued through duration of trials (most trials &le;24 weeks). Monitor all patients for notable changes in behavior that might indicate suicidal thoughts or depression; notify health care provider immediately if symptoms occur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use caution with renal impairment; dosage adjustment may be necessary. In patients with ESRD requiring hemodialysis, it is recommended that immediate-release formulations be used instead of ER formulations.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Children may have increased incidence of psychiatric symptoms; dose reduction or discontinuation may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Withdrawal: Anticonvulsants should not be discontinued abruptly because of the possibility of increasing seizure frequency; therapy should be withdrawn gradually to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299586\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187612\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9904&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brivaracetam: LevETIRAcetam may diminish the therapeutic effect of Brivaracetam. Specifically, the therapeutic effect of brivaracetam may be diminished and/or negligible when given to patients already receiving levetiracetam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine patches (Butrans brand) at 5 mcg/hr in adults when used with other CNS depressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: LevETIRAcetam may enhance the adverse/toxic effect of CarBAMazepine. CarBAMazepine may decrease the serum concentration of LevETIRAcetam. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is  not recommended.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin-Phenytoin: May decrease the serum concentration of LevETIRAcetam.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions.  Monitor anticonvulsant concentrations and treatment response closely with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: LevETIRAcetam may increase the serum concentration of Methotrexate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mianserin: May diminish the therapeutic effect of Anticonvulsants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.  Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orlistat: May decrease the serum concentration of Anticonvulsants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OXcarbazepine: May decrease the serum concentration of LevETIRAcetam.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PHENobarbital: May decrease the serum concentration of LevETIRAcetam.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Primidone: May decrease the serum concentration of LevETIRAcetam.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187637\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Food may delay, but does not affect the extent of absorption. Management: Administer without regard to meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187614\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187626\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse effects were observed in animal reproduction studies. Levetiracetam crosses the placenta and can be detected in the newborn following delivery (Johannessen 2005; Lopez-Fraile 2009; Tomson 2007). An increase in the overall rate of major congenital malformations has not been observed following maternal use of levetiracetam. Available studies have not been large enough to determine if there is an increased risk of specific birth defects (Hernandez-Diaz 2012; Mawhinney 2013; M&oslash;lgaard-Nielsen 2011; Vajda 2012). In general, maternal polytherapy with antiepileptic drugs may increase the risk of congenital malformations; monotherapy with the lowest effective dose is recommended. Newborns of women taking antiepileptic medications may be at an increased risk of SGA and a 1 minute APGAR score &lt;7 (Harden and Meader 2009). Plasma concentrations of levetiracetam gradually decrease during pregnancy, especially during the third trimester, due to physiologic changes which occur; patients should be monitored during pregnancy and postpartum. </p>\n    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">A registry is available for women exposed to levetiracetam during pregnancy: Pregnant women may enroll themselves into the North American Antiepileptic Drug (AED) Pregnancy Registry (888-233-2334 or http://www.aedpregnancyregistry.org/). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14385209\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Levetiracetam is present in breast milk.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The relative infant dose (RID) of levetiracetam is 7.9% when calculated using data derived from the highest breast milk concentration located and compared to a weight-adjusted maternal dose of 1,000 to 3,000 mg/day.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In general, breastfeeding is considered acceptable when the RID is &lt;10% (Anderson 2016; Ito 2000).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The RID of levetiracetam was calculated using an average milk:maternal plasma ratio of 1.05, providing an estimated daily infant dose via breast milk of ~2.4 mg/kg/day. This average milk:maternal plasma ratio was calculated using samples collected from 11 mother-infant pairs 4 to 23 days' postpartum following maternal administration of oral levetiracetam 1,000 to 3,000 mg/day. Concomitant maternal medications included lamotrigine, carbamazepine, tiagabine, clobazam, and/or oxcarbazepine which may have impacted maternal plasma concentrations. Levetiracetam was detected in the plasma of the breastfed infants (Tomson 2007).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Adverse effects, including hypotonia, sedation, vomiting, weight loss, and poor suckling have been reported in breastfed infants (Kramer 2002; Paret 2014). Insufficient lactation and subsequent discontinuation of breastfeeding has also been reported (Paret 2014).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Breastfeeding is not recommended by the manufacturer. Infants exposed to levetiracetam via breast milk should be monitored for adverse effects and for achievement of developmental milestones. Maternal plasma concentrations should be monitored postpartum.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7740244\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CNS depression (impaired coordination, ataxia, abnormal gait, weakness, fatigue, dizziness, and somnolence); psychiatric and behavioral symptoms (aggression, agitation, anger, anxiety, apathy, confusion, depersonalization, depression, emotional lability, hostility, hyperkinesias, irritability, nervousness, neurosis, suicidal thoughts and personality disorder); diastolic blood pressure in children 1 month to &lt;4 years; CBC (in patients who experience significant weakness, pyrexia, recurrent infections or coagulation disorders).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187606\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">The precise mechanism by which levetiracetam exerts its antiepileptic effect is unknown. However, several studies have suggested the mechanism may involve one or more of the following central pharmacologic effects: inhibition of voltage-dependent N-type calcium channels; facilitation of GABA-ergic inhibitory transmission through displacement of negative modulators; reduction of delayed rectifier potassium current; and/or binding to synaptic proteins which modulate neurotransmitter release.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187622\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Oral: Rapid and almost complete</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release: Food decreases C<sub>max</sub> by 20% and delays time to C<sub>max</sub> (T<sub>max</sub>) by 1.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release: Intake of a high-fat, high-calorie breakfast before the administration results in a higher C<sub>max</sub> and longer median T<sub>max</sub>; the median T<sub>max</sub> is 2 hours longer in the fed state</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: Similar to total body water</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children &lt;4 years: 0.63 &plusmn; 0.08 L/kg (Glauser 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 6 to 12 years: 0.72 &plusmn; 0.12 L/kg (Pellock 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 0.5 to 0.7 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: &lt;10%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Not extensive; 24% of dose is metabolized by enzymatic hydrolysis of acetamide group (major metabolic pathway; hydrolysis occurs primarily in the blood; not cytochrome P450 dependent); two minor metabolites (one via hydroxylation of 2-oxo-pyrrolidine ring and one via opening of the 2-oxo-pyrrolidine ring in position 5) are also formed; metabolites are inactive and renally excreted</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: 100%; bioavailability of extended release tablets is similar to immediate release tablets; tablets, oral solution, and injection are bioequivalent</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Increased in patients with renal impairment:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children &lt;4 years: 5.3 &plusmn; 1.3 hours (Glauser 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 4 to 12 years: 6 &plusmn; 1.1 hours (Pellock 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: ~6 to 8 hours; extended release tablet: ~7 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral solution: Fasting infants and children &lt;4 years: 1.4 &plusmn; 0.9 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Immediate release: Fasting adults and children: ~1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Extended release: ~4 hours; median time to peak is 2 hours longer in the fed state</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (66% as unchanged drug and 27% as inactive metabolites); undergoes glomerular filtration and subsequent partial tubular reabsorption</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Clearance: Correlated with creatinine clearance; clearance is decreased in patients with renal dysfunction</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &lt;6 months: 1.23 mL/minute/kg (Glauser 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children 6 months to 4 years: 1.57 mL/minute/kg (Glauser 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 6 to 12 years: 1.43 mL/minute/kg; 30% to 40% higher than adults on a per kg basis (Pellock 2001)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187625\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Keppra Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg/5 mL (5 mL): $63.64</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Keppra Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/mL (473 mL): $861.12</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (LevETIRAcetam in NaCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg/100 mL (100 mL): $33.30</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mg/100 mL (100 mL): $54.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1500 mg/100 mL (100 mL): $72.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (LevETIRAcetam Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg/5 mL (5 mL): $4.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (LevETIRAcetam Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/mL (473 mL): $307.74</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet Disintegrating Soluble</b> (Spritam Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (60): $575.96</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (60): $575.96</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750 mg (60): $575.96</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mg (60): $575.96</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Keppra XR Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (60): $513.46</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750 mg (60): $770.99</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (LevETIRAcetam ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (60): $266.82</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750 mg (60): $400.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Roweepra XR Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (60): $266.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750 mg (60): $400.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Keppra Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (120): $926.84</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (120): $1,132.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750 mg (120): $1,534.72</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mg (60): $1,132.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (LevETIRAcetam Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (120): $345.04</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (120): $421.71</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750 mg (120): $571.31</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mg (60): $422.18</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Roweepra Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (120): $120.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750 mg (120): $180.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mg (60): $120.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187628\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Callexe (AR);</li>\n      <li>Callexe XR (AR);</li>\n      <li>Ceumid (CR, DO, EC, GT, HN, NI, PA, SV, UY);</li>\n      <li>Citazar (BD);</li>\n      <li>Desitrend (GB);</li>\n      <li>Dretacen (NL);</li>\n      <li>E Keppra (JP);</li>\n      <li>Eletam (BD);</li>\n      <li>Epictal (IN);</li>\n      <li>Epilen (TW);</li>\n      <li>Epiletam (RO);</li>\n      <li>Epilev (HR);</li>\n      <li>Epsytam (PH);</li>\n      <li>Erata (BD);</li>\n      <li>Iracet (BD, LK);</li>\n      <li>Ivetra (PH);</li>\n      <li>Julitam (PH);</li>\n      <li>Kepcet (AU, DE);</li>\n      <li>Kepdin (PH);</li>\n      <li>Keppra (AE, AR, AT, AU, BB, BE, BG, BH, BM, BS, CH, CL, CN, CO, CR, CU, CY, CZ, DE, DK, DO, EC, EE, ES, FI, FR, GB, GR, GT, HK, HN, HR, HU, ID, IE, IL, IN, IS, IT, JM, JO, KR, KW, LB, LK, LT, LU, LV, MT, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PR, PT, QA, RO, RU, SA, SE, SG, SI, SK, SV, TH, TR, TT, TW, UA, VN);</li>\n      <li>Keppra I.V. (AU);</li>\n      <li>Keppra XR (BB);</li>\n      <li>Kerron (AU);</li>\n      <li>Kevesy (NL);</li>\n      <li>Kevtam (AU);</li>\n      <li>Kopodex (CL, CO, EC, PE, PY);</li>\n      <li>Laurak (ES);</li>\n      <li>Lecetam (TH);</li>\n      <li>Lethira (ID);</li>\n      <li>Letram (PH);</li>\n      <li>Lev Desitin (CH);</li>\n      <li>Levetam (UY);</li>\n      <li>Levetrim (IL);</li>\n      <li>Levetstad (VN);</li>\n      <li>Levim (TW);</li>\n      <li>Levipil (LK);</li>\n      <li>Levit (PH);</li>\n      <li>Levitam (ID);</li>\n      <li>Levron (AR);</li>\n      <li>Malomibe (VN);</li>\n      <li>Matever (EE, IE, MT, SE);</li>\n      <li>Nobelin (TW);</li>\n      <li>Normeg (EE);</li>\n      <li>Prepalepan (AT);</li>\n      <li>Repitend (EE);</li>\n      <li>Rivolev (UA);</li>\n      <li>Rivoleve (CH);</li>\n      <li>Tietari (SG);</li>\n      <li>Tiramaks (UA);</li>\n      <li>Torleva (IN, LK, VN);</li>\n      <li>Trund (NL);</li>\n      <li>Vexlev (PH);</li>\n      <li>Vitera (RO)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2015;63(11):2227-2246. doi:10.1111/jgs.13702.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-drug-information/abstract-text/26446832/pubmed\" target=\"_blank\" id=\"26446832\">26446832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Betts T, Waegemans T, and Crawford P, &ldquo;A Multicentre, Double-Blind, Randomized, Parallel Group Study to Evaluate the Tolerability and Efficacy of Two Oral Doses of Levetiracetam, 2000 mg Daily and 4000 mg Daily, Without Titration in Patients With Refractory Epilepsy,&rdquo; <i>Seizure</i>, 2000, 9(2): 80-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-drug-information/abstract-text/10845730/pubmed\" target=\"_blank\" id=\"10845730\">10845730</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brophy GM, Bell R, Claassen J, et al; Neurocritical Care Society Status Epilepticus Guideline Writing Committee. Guidelines for the evaluation and management of status epilepticus. <i>Neurocrit Care</i>. 2012;17(1):3-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-drug-information/abstract-text/22528274/pubmed\" target=\"_blank\" id=\"22528274\">22528274</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26069773\"></a>Chau K, Yong J, Ismail K, Griffith N, Liu M, Makris A. Levetiracetam-induced severe acute granulomatous interstitial nephritis. <i>Clin Kidney J</i>. 2012;5(3):234-236.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-drug-information/abstract-text/26069773/pubmed\" target=\"_blank\" id=\"26069773\">26069773</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ferrendelli JA, &ldquo;Concerns With Antiepileptic Drug Initiation: Safety, Tolerability, and Efficacy,&rdquo; <i>Epilepsia</i>, 2001, 42(Suppl 4):28-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-drug-information/abstract-text/11564122/pubmed\" target=\"_blank\" id=\"11564122\">11564122</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Glauser TA, Mitchell WG, Weinstock A, et al, &quot;Pharmacokinetics of Levetiracetam in Infants and Young Children With Epilepsy,&quot; <i>Epilepsia</i>, 2007, 48(6):1117-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-drug-information/abstract-text/17442002/pubmed\" target=\"_blank\" id=\"17442002\">17442002</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Glauser TA, Pellock JM, Bebin EM, et al, &ldquo;Efficacy and Safety of Levetiracetam in Children with Partial Seizures: An Open-label Trial,&rdquo; <i>Epilepsia</i>, 2002, 43(5):518-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-drug-information/abstract-text/12027913/pubmed\" target=\"_blank\" id=\"12027913\">12027913</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26900382\"></a>Glauser T, Shinnar S, Gloss D, et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the Guideline Committee of the American Epilepsy Society. <i>Epilepsy Curr</i>. 2016;16(1):48-61. doi:10.5698/1535-7597-16.1.48.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-drug-information/abstract-text/26900382/pubmed\" target=\"_blank\" id=\"26900382\">26900382</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Harden CL, Meador KJ, Pennell PB, et al. Practice parameter update: management issues for women with epilepsy--focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. <i>Neurology</i>. 2009;73(2):133-141.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Healthy Canadians Recalls and Alerts. KEPPRA (levetiracetam) &ndash; assessing the potential risk of acute kidney injury (acute renal failure/interstitial nephritis). Health Canada website. Available at http://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/keppra-eng.php. Published January 6, 2017. Accessed January 12, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hern&aacute;ndez-D&iacute;az S, Smith CR, Shen A, et al, &quot;Comparative Safety of Antiepileptic Drugs During Pregnancy,&quot; <i>Neurology</i>, 2012, 8(21):1692-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-drug-information/abstract-text/22551726/pubmed\" target=\"_blank\" id=\"22551726\">22551726</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hovinga CA, &ldquo;Levetiracetam: A Novel Antiepileptic Drug,&rdquo; <i>Pharmacotherapy</i>, 2001, 21(11):1375-88.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-drug-information/abstract-text/11714211/pubmed\" target=\"_blank\" id=\"11714211\">11714211</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Johannessen SI, Helde G, Brodtkorb E. Levetiracetam concentrations in serum and in breast milk at birth and during lactation. <i>Epilepsia</i>. 2005;46(5):775-777.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-drug-information/abstract-text/15857447 /pubmed\" target=\"_blank\" id=\"15857447 \">15857447 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Keppra injection (levetiracetam) [prescribing information]. Smyrna, GA: UCB Inc; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Keppra tablet and oral solution (levetiracetam) [prescribing information]. Smyrna, GA: UCB Inc; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Keppra XR (levetiracetam) [prescribing information]. Smyrna, GA: UCB Inc; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Keppra (levetiracetam) [product monograph]. Oakville, Ontario, Canada: UCB Canada Inc; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Koubeissi MZ, Amina S, Pita I, et al, &ldquo;Tolerability and Efficacy of Oral Loading of Levetiracetam,&rdquo; <i>Neurology</i>, 2008, 70(22 pt 2):2166-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-drug-information/abstract-text/18505995/pubmed\" target=\"_blank\" id=\"18505995\">18505995</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kramer G, Hosli I, Glanzmann R et al. Levetiracetam accumulation in human breast milk. <i>Epilepsia</i>. 2002;43 (Suppl 7):105.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levetiracetam in Sodium Chloride Injection [prescribing information]. Rockford, IL: Mylan Institutional; December 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levetiracetam injection, for intravenous use [prescibing information]. Lake Forest, IL: Hospira; September 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    L&oacute;pez-Fraile IP, Cid AO, Juste AO, Modrego PJ. Levetiracetam plasma level monitoring during pregnancy, delivery, and postpartum: clinical and outcome implications. <i>Epilepsy Behav</i>. 2009;15(3):372-375.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-drug-information/abstract-text/19362602 /pubmed\" target=\"_blank\" id=\"19362602 \">19362602 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mawhinney E, Craig J, Morrow J, et al. Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. <i>Neurology</i>. 2013;80(4):400-405.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-drug-information/abstract-text/23303847 /pubmed\" target=\"_blank\" id=\"23303847 \">23303847 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meador KJ, Gevins A, Loring DW, et al, &ldquo;Neuropsychological and Neurophysiologic Effects of Carbamazepine and Levetiracetam,&rdquo; <i>Neurology</i>, 2007, 69(22):2076-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-drug-information/abstract-text/18040014/pubmed\" target=\"_blank\" id=\"18040014\">18040014</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    M&oslash;lgaard-Nielsen D, Hviid A. Newer-generation antiepileptic drugs and the risk of major birth defects. <i>JAMA</i>. 2011;305(19):1996-2002.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-drug-information/abstract-text/21586715 /pubmed\" target=\"_blank\" id=\"21586715 \">21586715 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Paret N, Gouraud A, Bernard N, et al. Long-term follow-up of infants exposed to levetiracetam during breastfeeding: Comparison to a control group. <i>Birth Defects Res A Clin Mol Teratol</i>. 2014;100:537-538.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-drug-information/abstract-text/23911354 /pubmed\" target=\"_blank\" id=\"23911354 \">23911354 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pellock JM, Glauser TA, Bebin EM, et al, &quot;Pharmacokinetic Study of Levetiracetam in Children,&quot; <i>Epilepsia</i>, 2001, 42(12):1574-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-drug-information/abstract-text/11879369/pubmed\" target=\"_blank\" id=\"11879369\">11879369</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roberts GM, Majoie HJ, Leenen LA, et al, &ldquo;Ketter's Hypothesis of the Mood Effects of Antiepileptic Drugs Coupled to the Mechanism of Action of Topiramate and Levetiracetam,&rdquo; Epilepsy Behav, 2005, 6(3):366-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-drug-information/abstract-text/15820345/pubmed\" target=\"_blank\" id=\"15820345\">15820345</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sankar R and Holmes GL, &ldquo;Mechanisms of Action for the Commonly Used Antiepileptic Drugs: Relevance to Antiepileptic Drug-Associated Neurobehavioral Adverse Effects,&rdquo; <i>J Child Neurol</i>, 2004, 19(Suppl 1):6-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-drug-information/abstract-text/15032376/pubmed\" target=\"_blank\" id=\"15032376\">15032376</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24986483\"></a>Spengler DC, Montouris GD, Hohler AD. Levetiracetam as a possible contributor to acute kidney injury. <i>Clin Ther</i>. 2014;36(8):1303-1306.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-drug-information/abstract-text/24986483/pubmed\" target=\"_blank\" id=\"24986483\">24986483</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Spritam (levetiracetam) [prescribing information]. East Windsor, NJ: Aprecia Pharmaceuticals; June 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Szaflarski JP, Sangha KS, Lindsell CJ, Shutter LA. Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis. <i>Neurocrit Care</i>. 2010;12(2):165-172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-drug-information/abstract-text/19898966/pubmed\" target=\"_blank\" id=\"19898966\">19898966</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tomson T, Palm R, K&auml;ll&eacute;n K, et al, &quot;Pharmacokinetics of Levetiracetam During Pregnancy, Delivery, in the Neonatal Period, and Lactation,&quot; <i>Epilepsia</i>, 2007, 48(6):1111-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-drug-information/abstract-text/17381438/pubmed\" target=\"_blank\" id=\"17381438\">17381438</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Two New Drugs for Epilepsy,&rdquo; <i>Med Lett Drugs Ther</i>, 2000, 42(1076):33-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-drug-information/abstract-text/10803174/pubmed\" target=\"_blank\" id=\"10803174\">10803174</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vajda FJ, Graham J, Roten A, et al. Teratogenicity of the newer antiepileptic drugs--the Australian experience. <i>J Clin Neurosci</i>. 2012;19(1):57-59.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-drug-information/abstract-text/22104350 /pubmed\" target=\"_blank\" id=\"22104350 \">22104350 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Welty TE, Gidal BE, Ficker DM, et al, &ldquo;Levetiracetam: A Different Approach to the Pharmacotherapy of Epilepsy,&rdquo; <i>Ann Pharmacother</i>, 2002, 36(2):296-304.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-drug-information/abstract-text/11847952/pubmed\" target=\"_blank\" id=\"11847952\">11847952</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9904 Version 275.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F187641\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F187642\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F187668\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F187644\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F187656\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F187645\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F187646\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F187647\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F187617\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F187603\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F46216158\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874650\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F187620\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F187618\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25873118\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F187675\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F187610\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F187623\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F187607\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299586\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F187612\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F187637\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F187614\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F187626\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F14385209\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F7740244\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F187606\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F187622\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F187625\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F187628\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9904|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=levetiracetam-patient-drug-information\" class=\"drug drug_patient\">Levetiracetam: Patient drug information</a></li><li><a href=\"topic.htm?path=levetiracetam-pediatric-drug-information\" class=\"drug drug_pediatric\">Levetiracetam: Pediatric drug information</a></li></ul></div></div>","javascript":null}